CA
NZ
UK
AU
IND
US
…
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Aptorum Group Ltd is a Nasdaq-listed clinical-stage biopharmaceutical company focused on developing therapies and diagnostics addressing unmet medical needs, particularly in niche and rare disease areas. Its long-term growth drivers include advancement of clinical-stage programs, potential regulatory approvals and strategic partnerships or licensing that could support commercialization, which may benefit investors seeking early-stage biotech exposure.
Key risks include high clinical and regulatory failure risk, ongoing financing needs and limited market liquidity, alongside competitive pressure in specialty pharmaceutical markets; investors should monitor program progress and funding plans.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -1.38M | -4.16M | -4.34M | -11.53M | -27.11M |
| Minority interest | 0.01M | -0.11M | 1.52M | 1.73M | 2.07M |
| Net income | -1.36M | -4.27M | -2.83M | -5.31M | -25.29M |
| Selling general administrative | 1.64M | 1.46M | 4.37M | 7.87M | 7.70M |
| Selling and marketing expenses | - | - | 0.05M | 0.10M | 0.10M |
| Gross profit | 0.00M | -0.26M | 0.01M | 0.08M | 0.08M |
| Reconciled depreciation | 0.00M | 0.31M | 1.13M | 1.21M | 1.19M |
| Ebit | - | -4.01M | -10.60M | -22.96M | -19.06M |
| Ebitda | -1.82M | -3.76M | -9.48M | -21.76M | -17.87M |
| Depreciation and amortization | - | 0.26M | 1.12M | 1.21M | 1.19M |
| Operating income | -1.82M | -3.80M | -10.60M | -22.96M | -19.06M |
| Other operating expenses | 1.82M | 3.80M | 11.03M | 18.81M | 20.75M |
| Interest expense | 0.10M | 0.15M | 0.12M | 0.15M | 0.09M |
| Interest income | - | - | - | 0.15M | - |
| Net interest income | -0.10M | -0.15M | -0.12M | 0.15M | -0.09M |
| Income tax expense | - | - | -1.52M | -6.21M | -1.83M |
| Total revenue | 0.00M | 0.00M | 0.43M | 1.30M | 1.54M |
| Total operating expenses | 1.82M | 3.54M | 10.61M | 17.59M | 19.29M |
| Cost of revenue | 0.00M | 0.26M | 0.42M | 1.22M | 1.46M |
| Total other income expense net | 0.44M | -0.36M | 6.26M | 11.44M | -8.05M |
| Net income from continuing ops | -1.38M | -4.16M | -4.34M | -11.53M | -27.11M |
| Net income applicable to common shares | - | - | - | - | -25.05M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 18.69M | 16.13M | 20.64M | 20.87M | 21.91M |
| Intangible assets | - | - | 0.15M | 0.75M | 0.88M |
| Other current assets | 0.14M | 0.08M | 0.40M | 4.88M | 0.65M |
| Total liab | 4.90M | 4.35M | 5.26M | 13.03M | 4.40M |
| Total stockholder equity | 23.12M | 21.13M | 24.85M | 15.71M | 23.61M |
| Other current liab | 1.07M | 1.00M | 1.89M | 6.18M | 4.18M |
| Common stock | 0.00M | 0.00M | 0.00M | 35.71M | 35.64M |
| Capital stock | 0.00M | 0.00M | 0.00M | 35.71M | 35.64M |
| Retained earnings | -73.79M | -72.43M | -68.16M | -65.34M | -55.54M |
| Other assets | - | - | - | - | 0.30M |
| Cash | 3.45M | 0.87M | 2.01M | 1.88M | 8.13M |
| Total current liabilities | 4.59M | 4.34M | 2.10M | 12.50M | 4.38M |
| Net debt | 0.07M | 2.48M | 1.36M | 4.97M | -7.91M |
| Short term debt | 3.52M | 3.34M | 0.20M | 6.32M | 0.19M |
| Short long term debt | 3.42M | 3.24M | - | 6.01M | - |
| Short long term debt total | 3.52M | 3.35M | 3.36M | 6.85M | 0.22M |
| Other stockholder equity | 97.00M | 93.47M | 93.02M | 45.31M | 43.51M |
| Property plant equipment | - | - | - | - | 3.89M |
| Total current assets | 3.59M | 0.96M | 2.48M | 7.07M | 12.69M |
| Long term investments | 15.10M | 15.10M | 16.10M | 9.74M | 4.16M |
| Net tangible assets | - | - | - | - | 22.73M |
| Short term investments | - | - | 0.00M | 0.10M | 0.24M |
| Net receivables | - | 0.00M | 0.07M | 1.41M | 3.63M |
| Long term debt | - | - | 3.06M | 0.50M | - |
| Inventory | - | - | 0.00M | 0.03M | 0.04M |
| Accounts payable | - | - | - | - | 4.17M |
| Accumulated other comprehensive income | -0.09M | 0.09M | -0.01M | 0.03M | -0.00M |
| Non currrent assets other | - | 0.07M | 0.07M | 0.13M | 0.15M |
| Non current assets total | 15.10M | 15.17M | 18.16M | 13.80M | 9.22M |
| Capital lease obligations | 0.02M | 0.12M | 0.22M | 0.34M | 0.22M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.00M | 0.06M | 0.62M | 2.44M | 20.12M |
| Change to liabilities | - | - | - | - | 0.86M |
| Total cashflows from investing activities | - | 0.06M | 0.62M | - | 16.51M |
| Net borrowings | 0.00M | 0.00M | 2.50M | - | -2.04M |
| Total cash from financing activities | 4.41M | 0.00M | 4.09M | 6.63M | 2.78M |
| Change to operating activities | - | - | - | - | 0.18M |
| Net income | -1.36M | -4.27M | -4.34M | -11.53M | -27.11M |
| Change in cash | 2.58M | -1.13M | -3.01M | -3.25M | 4.64M |
| Begin period cash flow | 0.87M | 2.01M | 5.01M | 8.26M | 3.63M |
| End period cash flow | 3.45M | 0.87M | 2.01M | 5.01M | 8.26M |
| Total cash from operating activities | -1.84M | -1.19M | -7.72M | -12.32M | -14.65M |
| Issuance of capital stock | 5.07M | 0.00M | 1.58M | 0.01M | 4.00M |
| Depreciation | 0.00M | 0.26M | 1.13M | 1.21M | 1.19M |
| Other cashflows from investing activities | - | - | 0.52M | - | -3.36M |
| Change to inventory | 0.00M | 0.00M | 0.01M | 0.01M | 0.00M |
| Change to account receivables | 0.00M | 0.04M | 0.42M | -0.10M | -0.02M |
| Other cashflows from financing activities | - | - | -0.04M | 6.67M | 4.32M |
| Change to netincome | - | - | - | - | 8.19M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.19M | 0.14M |
| Change in working capital | -0.10M | -0.21M | 0.41M | 1.40M | 1.02M |
| Stock based compensation | 0.00M | 0.00M | 1.27M | 1.65M | 1.68M |
| Other non cash items | -0.37M | 3.03M | -6.18M | -5.05M | 0.61M |
| Free cash flow | -1.84M | -1.19M | -7.73M | -12.51M | -14.79M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NVO Novo Nordisk A/S |
0.29 0.72% |
40.29 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
5.51 0.99% |
564.39 | 30.22 | 24.27 | 10.36 | 6.50 | 9.99 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
34.06 3.67% |
961.95 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| ARGNF argenx SE |
- -% |
900.30 | 45.77 | 31.25 | 13.84 | 7.12 | 11.38 | 36.06 |
Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.
116 Village Boulevard, Princeton, NJ, United States, 08540
609 951 2222
1
| Name | Title | Year Born |
|---|---|---|
| Mr. Darren Lui | CEO, Chief Accounting Officer & Exec. Director | 1982 |
| Mr. Chung Yuen Huen | Founder & Non-Exec. Director | 1981 |
| Dr. Clark Cheng | Chief Medical Officer & Exec. Director | 1980 |
| Dr. Wai Yip Lee | Head of R&D | 1974 |
| Mr. Martin Siu | Head of Fin. | NA |
| Mr. Chung Yuen Huen | Founder, CEO & Non-Executive Director | 1980 |
| Mr. Martin Siu | Head of Finance | 1979 |
| Mr. Kwok Kuen Wong | Head of Finance | 1956 |
| Mr. Chung Yuen Huen | Founder, CEO & Executive Director | 1980 |
| Mr. Kwok Kuen Wong | Head of Finance | 1956 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.80%
Communication Services
+0.61%
Consumer Cyclical
+1.47%
Consumer Defensive
+0.78%
Energy
-1.20%
Financial Services
+0.87%
Financials
+0.88%
Healthcare
-0.33%
Industrials
+0.85%
Real Estate
+0.50%
Technology
+0.39%
Utilities
+0.03%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...